Sofregen Medical raises US$8 million in Series B funding round

Date: 2019-12-18   Author: Pankaj Singh  Category: #news

Sofregen Medical raises US$8 million in Series B funding round

The funding will be used to support the commercialization and accessibility of Silk Voice™

Sofregen Medical, Inc., a biotech firm focused on developing advanced lineup of products based on silk protein, dubbed fibroin, has recently secured $8 million from a Series B funding round. According to reliable sources, the raised funding would be used to accelerate the advancement of the firm’s unique technology and support the availability and commercialization of Silk Voice™.

Sofregen has also revealed that it would be appointing Jonathan T. Hartmann as its CEO. For the record, Hartmann used to work for Axsun Technologies before. Sofregen believes that Hartmann would perfectly fit in and would benefit the company with his deep knowledge about the medical technology industry. In addition to this, the firm has also chosen Philippe Schaison to sit in its Board of Directors.  

Speaking of the company, Hartmann said that Sofregen is pioneering the medical sector and this progress has been possible due to the constant support from its outstanding team, an incredible platform of scientific & clinical research and strong financial backing.

The company is looking forward to creating a meaningful difference in patient's lives by introducing Silk Voice™ in 2020. Moreover, the firm would be developing clinical science to back the use of its exclusive silk protein item for medical aesthetics, he added.

Reportedly, the U.S. FDA (Food and Drug Administration) had earlier this year approved Silk Voice™ for enhancing vocal fold tissue for phonation development. Apparently, the move marked as the first product developed from solubilized silk protein that has been approved by the FDA.

Experts suggest that the product has the potential to considerably enhance treatment for the condition with the help of its unique material properties based on silk protein scaffold and trademarked single-use catheter delivery system.

As for Howard J. Weisman, Co-founder & Executive Chairman, Sofregen, the company is thrilled to bring Silk Voice and its awaited delivery system to the U.S. market and are looking forward to expanding its reach to other markets as well.

Source Credit: https://www.ptcommunity.com/wire/soft-tissue-engineering-biotechnology-company-sofregen-raises-8-million-series-b-funding-round



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Antenatal Screening Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2028

Author: Ashwin Naphade

Global Antenatal Screening Market, 2022-2028 Research Report provides crucial statistics on the market status of the Global Antenatal Screening manufacturers and is a respected source of guidance and direction for companies and individuals interes...


Pediatric Vitrectomy Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2028

Author: Ashwin Naphade

Global Pediatric Vitrectomy market report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Pediatric Vitrectomy market repor...


Legionnaire Disease Testing Market Comprehensive Analysis, Share, Growth Forecast from 2022 to 2028c

Author: Ashwin Naphade

This report studies the Global Legionnaire Disease Testing market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, ...